226 related articles for article (PubMed ID: 28394262)
21. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
22. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
23. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
24. p53 mediates senescence-like arrest induced by chronic replicational stress.
Marusyk A; Wheeler LJ; Mathews CK; DeGregori J
Mol Cell Biol; 2007 Aug; 27(15):5336-51. PubMed ID: 17515610
[TBL] [Abstract][Full Text] [Related]
25. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
26. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma.
Liu DD; Kang Y
Genes Dev; 2017 Sep; 31(18):1823-1824. PubMed ID: 29051386
[TBL] [Abstract][Full Text] [Related]
27. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
28. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
29. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
Alam SK; Yadav VK; Bajaj S; Datta A; Dutta SK; Bhattacharyya M; Bhattacharya S; Debnath S; Roy S; Boardman LA; Smyrk TC; Molina JR; Chakrabarti S; Chowdhury S; Mukhopadhyay D; Roychoudhury S
Cell Death Differ; 2016 Apr; 23(4):707-22. PubMed ID: 26494468
[TBL] [Abstract][Full Text] [Related]
30. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.
Linzen U; Lilischkis R; Pandithage R; Schilling B; Ullius A; Lüscher-Firzlaff J; Kremmer E; Lüscher B; Vervoorts J
PLoS One; 2015; 10(4):e0123736. PubMed ID: 25860957
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Rel/Nuclear Factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development.
van Hogerlinden M; Auer G; Toftgård R
Oncogene; 2002 Jul; 21(32):4969-77. PubMed ID: 12118375
[TBL] [Abstract][Full Text] [Related]
32. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
33. Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.
Slatter TL; Hung N; Bowie S; Campbell H; Rubio C; Speidel D; Wilson M; Baird M; Royds JA; Braithwaite AW
Cell Death Dis; 2015 Jun; 6(6):e1783. PubMed ID: 26068791
[TBL] [Abstract][Full Text] [Related]
34. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
35. Tumorigenic effect of nonfunctional p53 or p21 in mice mutant in the Werner syndrome helicase.
Lebel M; Cardiff RD; Leder P
Cancer Res; 2001 Mar; 61(5):1816-9. PubMed ID: 11280729
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers.
Park S; Oh AY; Cho JH; Yoon MH; Woo TG; Kang SM; Lee HY; Jung YJ; Park BJ
Mol Cancer Res; 2018 Jun; 16(6):935-946. PubMed ID: 29545477
[TBL] [Abstract][Full Text] [Related]
37. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
38. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
[TBL] [Abstract][Full Text] [Related]
39. Cross talk between stimulated NF-kappaB and the tumor suppressor p53.
Schneider G; Henrich A; Greiner G; Wolf V; Lovas A; Wieczorek M; Wagner T; Reichardt S; von Werder A; Schmid RM; Weih F; Heinzel T; Saur D; Krämer OH
Oncogene; 2010 May; 29(19):2795-806. PubMed ID: 20190799
[TBL] [Abstract][Full Text] [Related]
40. CHK1 and replicative stress in T-cell leukemia: Can an irreverent tumor suppressor end up playing the oncogene?
Sarmento LM; Barata JT
Adv Biol Regul; 2016 Jan; 60():115-121. PubMed ID: 26527132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
